2010
DOI: 10.1056/nejmoa1007056
|View full text |Cite
|
Sign up to set email alerts
|

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

Abstract: SUMMARYInflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

7
544
0
5

Year Published

2011
2011
2020
2020

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 778 publications
(556 citation statements)
references
References 23 publications
(27 reference statements)
7
544
0
5
Order By: Relevance
“…[15][16][17] Therefore, the identification of ALK rearrangements in other tumor types has gained importance owing to the potential for a similar treatment response. 19 Rearrangement of ALK has recently been reported in pediatric RCC. 20,21 However, to our knowledge, no study has yet studied ALK alterations in a large series of adult RCC.…”
Section: Discussionmentioning
confidence: 99%
“…[15][16][17] Therefore, the identification of ALK rearrangements in other tumor types has gained importance owing to the potential for a similar treatment response. 19 Rearrangement of ALK has recently been reported in pediatric RCC. 20,21 However, to our knowledge, no study has yet studied ALK alterations in a large series of adult RCC.…”
Section: Discussionmentioning
confidence: 99%
“…Pazopanib, a multitargeted tyrosine kinase inhibitor has demonstrated single-agent activity in patients with advanced STS subtypes except liposarcomas (Sleijfer et al, 2009). Crizotinib and Sirolimus has shown promising results in specific subgroups of STS (Bissler et al, 2008;Butrynski et al, 2010). Drugs like trabectedin, TK-inhibitors or m-TOR inhibitors are not commonly used in TR.…”
Section: Discussionmentioning
confidence: 99%
“…10 Histology shows inflamed fibrous and granulation tissue along with reactive blood vessels. 11 Surgery is warranted because the clinical and radiological appearance often suggest malignancy. 12 Role of radiotherapy and chemotherapy has not yet been proved.…”
Section: Discussionmentioning
confidence: 99%